ImmunoCellular Therapeutics, Ltd.(NYSE Amex Equities : IMUC)
IMUC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
Loading IMUC News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||1.64%||68.22||1.0%||$511.57m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.25%||371.39||2.7%||$306.45m|
|VRTX||Vertex Pharmaceuticals Incorporated||-0.79%||116.34||1.8%||$289.18m|
|ALXN||Alexion Pharmaceuticals, Inc.||0.15%||120.73||1.6%||$213.99m|
|NBIX||Neurocrine Biosciences, Inc.||-0.63%||53.28||4.5%||$109.21m|
|BMRN||BioMarin Pharmaceutical Inc.||2.00%||96.07||4.3%||$103.70m|
|KITE||Kite Pharma, Inc.||2.77%||82.80||15.6%||$98.74m|
|CLVS||Clovis Oncology, Inc.||1.35%||58.64||18.2%||$88.77m|
|A||Agilent Technologies, Inc.||0.06%||54.84||1.6%||$88.10m|
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. The company was founded on January 31, 2006 and is headquartered in Calabasas, CA.